MedPath

The Effect of Coenzyme Q10 on Hearing and Tinnitus Characteristics of Chronic Tinnitus Patients

Not Applicable
Conditions
Tinnitus
Registration Number
NCT02353650
Lead Sponsor
University Hospital, Antwerp
Brief Summary

The study is a randomised double-blinded trial. A group of 40 tinnitus patients with a naturally low Q10 level will be selected out of a preselected group of 160 screened out of a pre-existed database or patients which visited the ENT-consultation. The 40 patients with the lowest level will be asked to take 2 months Q10 (n=20) or the placebo (n=20). To evaluate the effect on hearing and tinnitus characteristic; audiometric test, tinnitus analysis and auditory evoked responses will be used as outcome measurements.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • chronic non-pulsatile tinnitus > 3 months
  • tinnitus has a clear otological cause
  • age > 18 years
Exclusion Criteria
  • pulsatile tinnitus
  • persons who take already Q10
  • pregnancy
  • cervical tinnitus
  • holocranial tinnitus
  • depression
  • mental of neurological disorders
  • history of chemotherapy
  • middle ear diseases

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Tinnitus Functional Index2 months
Secondary Outcome Measures
NameTimeMethod
Hospital Anxiety and Depression Scale2 months
Hyperacusis Questionnaire2 months
Audiometric tresholds test2 months
Tinnitus Analysis _ loudness matches2 months
Tinnitus Analysis_Minimal masking level2 months
Visual Analogue Scale of loudness2 months

Trial Locations

Locations (1)

University hospital of Antwerp

🇧🇪

Edegem, Antwerp, Belgium

© Copyright 2025. All Rights Reserved by MedPath